Loading…
Purple Biotech Ltd is projected to rise to $3.82 by 2027, a +28% move from its current price of $2.98. PPBT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.83 | $2.98 | $3.14 | +0.01% |
| May 30 | $2.77 | $2.98 | $3.20 | +0.02% |
| May 31 | $2.73 | $2.98 | $3.26 | +0.03% |
| Jun 1 | $2.69 | $2.98 | $3.30 | +0.04% |
| Jun 2 | $2.66 | $2.98 | $3.34 | +0.05% |
| Jun 3 | $2.63 | $2.98 | $3.38 | +0.06% |
| Jun 4 | $2.61 | $2.98 | $3.41 | +0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.61 | $2.98 | $3.41 | +0.07% |
| Week 2 | $2.47 | $2.98 | $3.61 | +0.14% |
| Week 3 | $2.36 | $2.99 | $3.77 | +0.21% |
| Week 4 | $2.28 | $2.99 | $3.91 | +0.28% |
| Week 5 | $2.21 | $2.99 | $4.04 | +0.35% |
| Week 6 | $2.15 | $2.99 | $4.16 | +0.42% |
| Week 7 | $2.10 | $2.99 | $4.28 | +0.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Purple Biotech Ltd (PPBT) is a clinical-stage healthcare company focused on oncology. It is currently priced at $2.88 per share with a market capitalization of $4.4M and a market rank of 5377. The current price sits within a forecasted path where the 2026 average is $2.88 with a neutral outlook, and subsequent years show a potential rise to higher price levels under a bullish to highly bullish trajectory in later years.
The forecast series provides a spectrum of outcomes, including a 2027 average of $3.73 and a 2040 average of $6.49, with a 2050 average of $9.08, illustrating a potential long-run upside despite near-term uncertainty. These figures underline a market position where near-term price action is constrained, but longer-term possibilities exist according to the projected pathway.
A major floor 56.6% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 66.1% above — a clean break opens room to run.
A major ceiling 122.8% above — clearing it would confirm fresh momentum.
Key PPBT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PPBT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.89 | Buy | $3.02 | Sell |
| MA 10 | $3.33 | Sell | $3.26 | Sell |
| MA 20 | $3.72 | Sell | $3.58 | Sell |
| MA 50 | $4.02 | Sell | $4.10 | Sell |
| MA 100 | $4.87 | Sell | $5.20 | Sell |
| MA 200 | $7.14 | Sell | $10.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 33.92 | Neutral |
| Stoch RSI (14) | 39.28 | Neutral |
| CCI (20) | -112.10 | Sell |
| Williams %R (14) | -80.35 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -27.76 | Sell |
| Bollinger %B (20,2) | 0.14 | Neutral |
| Stochastic %K (14) | 19.65 | Buy |
| TRIX (15) | -0.85 | Sell |
| Awesome (5,34) | -1.13 | Sell |
| Ultimate (7,14,28) | 24.59 | Buy |
| Momentum (10) | -0.87 | Sell |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 2.66 | Buy |
| ADX (14) | 22.73 | Sell |
| ATR (14) | 0.18 | Info |
The near-term technical picture remains bearish, with the RSI at 30 suggesting oversold conditions. The stock trades with the 50-day simple moving average at $4.06 and the 200-day simple moving average at $7.32, indicating downward pressure relative to longer-term trends. The 30-day price range spans from $2.02 to $4.10, showing a broad consolidation band.
Key support is positioned at $2.70, with resistance at $4.95, framing a zone where a breakout would be needed to shift the short-term bias.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.70 | $2.98 | $4.79 | 0% | Neutral | |
| $2.78 | $3.82 | $5.69 | +28% | Bullish | |
| $2.74 | $3.99 | $6.30 | +34% | Bullish | |
| $2.55 | $3.90 | $6.45 | +31% | Bullish | |
| $1.91 | $3.05 | $5.25 | +3% | Neutral | |
| $2.04 | $3.39 | $6.01 | +14% | Neutral | |
| $2.14 | $3.71 | $6.78 | +24% | Bullish | |
| $2.26 | $4.06 | $7.61 | +36% | Bullish | |
| $2.73 | $5.09 | $9.78 | +71% | Bullish | |
| $2.62 | $5.06 | $9.94 | +70% | Bullish | |
| $2.96 | $6.57 | $14.14 | +120% | Bullish | |
| $4.23 | $9.41 | $21.63 | +216% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.70 | $2.98 | $3.54 | +0.00% |
| June 2026 | $2.45 | $2.93 | $3.63 | -1.75% |
| July 2026 | $2.47 | $3.01 | $3.82 | +2.71% |
| August 2026 | $2.64 | $3.25 | $4.20 | +8.07% |
| September 2026 | $2.59 | $3.23 | $4.23 | -0.77% |
| October 2026 | $2.47 | $3.10 | $4.13 | -3.77% |
| November 2026 | $2.60 | $3.29 | $4.43 | +6.07% |
| December 2026 | $2.75 | $3.52 | $4.79 | +6.86% |
Click any year to see its month-by-month PPBT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PPBT is projected to trade between $2.70 and $4.79, averaging $2.98 — a potential gain of 0% from today's $2.98. A consolidation phase looks the most probable path here.
Purple Biotech Ltd's 2027 outlook centres on $3.82, within a $2.78 to $5.69 range. That is up +28% on the projected 2026 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2028, PPBT could reach as high as $6.30, with a base case around $3.99 and support toward $2.74 — roughly +34% from $2.98. Buyers look set to stay in control over this stretch.
Expect PPBT to range from $2.55 to $6.45 through 2029. The $3.90 average target implies a +31% move from current prices. That is -2% versus the projected 2028 average. Momentum favours further upside here.
The PPBT price prediction for 2030 points to an average of $3.05 (low $1.91, high $5.25) — a potential gain of +3% on today's $2.98. A consolidation phase looks the most probable path here.
In 2031, PPBT is projected to trade between $2.04 and $6.01, averaging $3.39 — a potential gain of +14% from today's $2.98. That is up +11% on the projected 2030 average. Price action looks broadly range-bound.
Purple Biotech Ltd's 2032 outlook centres on $3.71, within a $2.14 to $6.78 range. That is up +9% on the projected 2031 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, PPBT could reach as high as $7.61, with a base case around $4.06 and support toward $2.26 — roughly +36% from $2.98. Momentum favours further upside here.
Expect PPBT to range from $2.73 to $9.78 through 2034. The $5.09 average target implies a +71% move from current prices. That is up +25% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The PPBT price prediction for 2035 points to an average of $5.06 (low $2.62, high $9.94) — a potential gain of +70% on today's $2.98. Momentum favours further upside here.
In 2040, PPBT is projected to trade between $2.96 and $14.14, averaging $6.57 — a potential gain of +120% from today's $2.98. That is up +30% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Purple Biotech Ltd's 2050 outlook centres on $9.41, within a $4.23 to $21.63 range. That is up +43% on the projected 2040 average. That marks a +216% change versus current levels. Momentum favours further upside here.
Investing $1,000 in PPBT today (≈ 335.57047 PPBT) could be worth
$3,156.1
+$2,156.1 (+216%) by 2050 · US Dollar
Based on the average projected PPBT price of $9.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PPBTwould be worth at today's price.
$1,000 invested in PPBT on May 27, 2025 (≈ 42.643922 PPBT) would be worth
$127.08
-$872.92 (-87.3%) today · 0.13× · US Dollar
Based on a PPBT entry price of $23.45 vs. today's $2.98.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.98 | $1,000 | -0.0% |
| 1 month ago | $4.59 | $649.24 | -35.1% |
| 3 months ago | $4.98 | $598.39 | -40.2% |
| 6 months ago | $8.26 | $360.77 | -63.9% |
| 1 year ago | $23.45 | $127.08 | -87.3% |
| All time (5.0y) ago | $1,234 | $2.41 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PPBT forecast.
Our base-case forecast reaches $6.00 around 2040.
Implied market cap at $6.00: $5.59M
The multi-year forecast implies a mixed but increasingly bullish trajectory beyond 2026. For 2030, the average price is projected at $2.92 with a minimum of $1.80 and a maximum of $5.10, yielding a modest 1.5% ROI and a neutral sentiment. Looking further out, 2040 shows a dramatic potential rise to an average of $6.49 with a max of $14.28 and an ROI of 125.4%, supported by a bullish outlook.
By 2050 the forecast envisions an average of $9.08, a max of $20.88, and an ROI of 215.3% with continued bullish sentiment. A notable near-term driver is the collaboration with Bristol Myers Squibb to evaluate CM24 with nivolumab, which could act as a catalyst if clinical results remain favorable. These are estimates, not guarantees, and depend on clinical and regulatory developments for a biotech in an early-stage pipeline.
Tap a question to reveal the answer.
2030 avg price is $2.92 with a min of $1.80 and a max of $5.10, ROI 1.5%, sentiment Neutral.
The forecast shows a neutral outlook in 2026 with an avg of $2.88 and ROI 0%, followed by bullish momentum in several later years (e.g., 2027 avg $3.73, ROI 29.4%; 2034 avg $5.03, ROI 74.7%; 2040 avg $6.49, ROI 125.4%; 2050 avg $9.08, ROI 215.3%). These are estimates and not guarantees.
Yes. The max forecast values exceed $5 in multiple years, for example 2030 max $5.10, 2033 max $7.47, 2034 max $9.85, 2040 max $14.28, and 2050 max $20.88.
Current price is $2.88 and market cap is $4.4M.
Bearish sentiment with RSI around 30. The 30-day range is $2.02 to $4.10, with a support at $2.70 and resistance at $4.95.
Purple Biotech Ltd Community Discussion
0Share your Purple Biotech Ltd price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.